Tgf-ß inhibitors

A method for treating a disease or condition mediated by or involving a member of the TGF-β receptor superfamily in a subject in need thereof, comprising administering an effective TGF-β receptor superfamily inhibiting amount of a compound having the structure of formula (I):

• or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a solvate or hydrate thereof,
• wherein
• A is phenyl optionally substituted with one to five R1 groups, wherein each R1 is independently halogen, cyano, —ORa, —SRa, —N(Ra)2, C1-6 alkyl, C1-6haloalkyl or C3-8cycloalkyl,
• wherein each Ra is independently hydrogen, C1-6 alkyl or C1-6 haloalkyl;
• Z is
• a fused bicyclic ring of the formula,
• wherein
• ring A is phenyl or pyrazole,
• optionally substituted with one to four R2 groups, wherein each R2 is independently halogen, C1-6alkyl, C1-6haloalkyl, —ORb, —C(O)NRb2, —C(O)CH2NRb2, —CH2—OP(O)(ORc)2, or heteroaryl,
• wherein each Rb is independently hydrogen, C1-6 alkyl or C1-6haloalkyl, and
• wherein each Rc is independently hydrogen or C1-6 alkyl;
• ring B is phenyl or pyridyl, each optionally substituted with one to three R3 groups,
• wherein each R3 is independently halogen, C1-6alkyl, C1-6haloalkyl, cycloalkyl or heteroaryl;
• R and R′ are independently hydrogen, halogen, C1-6alkyl or C1-6 haloalkyl;
• and
• wherein each alkyl, haloalkyl cycloalkyl or heteroaryl group is optionally substituted with one or two —RZ groups that are each independently halogen, C1-6alkyl or C1-6haloalkyl.